ADMA

$11.11+0.45%visit website

ADMA BIOLOGICS, INC.

Market Cap

$2.5B

Live price × SEC shares (Jul 31, 2026)

Sector

Health Care

Industry

Biotechnology

Beta (raw)

0.67

60mo monthly vs SPY

P/E (TTM)

15.9

TTM to Jun 2026 · diluted EPS

P/S (TTM)

4.9

TTM to Jun 2026 · revenue

P/B

6.1

Mkt cap / shareholders' equity

EV/EBITDA (TTM)

11.0

TTM to Jun 2026 · EV incl. net debt

Loading…

Financial Statements

USD thousands	Q3 FY2025 Sep 30, 2025	Q4 FY2025 Dec 31, 2025	Q1 FY2026 Mar 31, 2026	Q2 FY2026 Jun 30, 2026	TTM Jun 30, 2026
Revenue	134,224	139,163	114,493	124,395	512,275
Cost of revenue	58,598	50,347	33,743	38,118	180,806
Gross profit	75,626	88,816	80,750	86,277	331,469
Research & development	1,528	1,376	2,597	6,014	11,515
Selling, general & administrative	21,776	23,512	26,742	26,737	98,767
Total operating expenses	24,614	26,065	22,476	33,832	106,987
Operating income	51,012	62,751	58,274	52,445	224,482
Interest expense	1,675	1,626	2,100	3,424	8,825
Pretax income	47,515	61,595	57,127	50,237	216,474
Income tax	11,087	12,216	11,799	12,415	47,517
Net income	36,428	49,379	45,328	37,822	168,957
EPS (basic) ($)	0.15		0.19	0.17	0.72
EPS (diluted) ($)	0.15		0.19	0.16	0.70
Weighted avg. shares (basic)	238,603		236,073	228,233
Weighted avg. shares (diluted)	244,664		239,956	230,337

Source: SEC XBRL filings (10-K, 10-Q). Per-share data in dollars; shares in thousands. Latest: 10-Q filed Aug 5, 2026, period ended Jun 30, 2026. flagged for review— withheld, failed a consistency check restated or split-adjustedhover a value for its source

Showing the last 5 quarters. 60 more quarters, back to Sep 2010, with Tormere Pro.

Corporate Events (8-K)

9 filings in 12 months · 0 with priority itemsFull history →

Filed	Items	Filing
Aug 5, 2026 accepted 4:10 PM ET	2.02Earnings release	Document SEC ↗
Jun 2, 2026 accepted 4:05 PM ET	5.07Shareholder vote	Document SEC ↗
May 6, 2026 accepted 4:10 PM ET	2.02Earnings release	Document SEC ↗
May 4, 2026 accepted 7:05 AM ET	8.01Other events	Document SEC ↗
Mar 27, 2026 accepted 7:05 AM ET	7.01Reg FD disclosure	Document SEC ↗
Mar 2, 2026 accepted 7:05 AM ET	7.01Reg FD disclosure8.01Other events	Document SEC ↗
Feb 25, 2026 accepted 4:11 PM ET	2.02Earnings release5.02Officer / director change	Document SEC ↗
Jan 12, 2026 accepted 8:20 AM ET	2.02Earnings release7.01Reg FD disclosure	Document SEC ↗
Nov 5, 2025 accepted 4:11 PM ET	2.02Earnings release	Document SEC ↗
Aug 6, 2025 accepted 4:11 PM ET	1.01Material agreement1.02Agreement terminated2.02Earnings release2.03New debt obligation	Document SEC ↗

Signals

purchases / sales, 90d

Short Volume

60%

W/W +18.1pp

Market & Alt Data

News

Factor Profile

Pro

Pro feature

Fama-French factor analysis is available on the Pro plan.

Upgrade to Pro

Sort by

Type

Trade Date	Filed	Owner	Role	Type	Shares	Price	Value	Owned After
2026-05-27	2026-05-28	Grossman Jerrold B	Director	Purchase	6,400	$7.91	$51K	520.3K	View
2026-05-12	2026-05-14	Grossman Jerrold B	Director	Purchase	12.5K	$8.01	$100K	513.9K	View
2026-05-11	2026-05-12	Grossman Jerrold B	Director	Purchase	12.5K	$8.01	$100K	501.4K	View
2026-03-16	2026-03-17	Grossman Adam S	Director & President and CEO	Sale	21.0K	$15.16	$318K	2.11M	View
2026-03-09	2026-03-10	Kestenberg-Messina Kaitlin M.	COO and SVP, Compliance	Sale	10.1K	$15.63	$158K	466.6K	View